Total Payments
$376,635
2024 Payments
$80.42
Companies
9
Transactions
37
Medicare Patients
2,184
Medicare Billing
$118,366
Payment Breakdown by Category
Research$373,673 (99.2%)
Travel$1,990 (0.5%)
Food & Beverage$971.38 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $373,673 | 12 | 99.2% |
| Travel and Lodging | $1,990 | 9 | 0.5% |
| Food and Beverage | $971.38 | 16 | 0.3% |
Payments by Type
Research
$373,673
12 transactions
General
$2,961
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $371,590 | 9 | $0 (2022) |
| Allergan Inc. | $3,570 | 10 | $0 (2019) |
| Merck Sharp & Dohme LLC | $1,042 | 10 | $0 (2024) |
| Eli Lilly and Company | $224.00 | 2 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $113.43 | 2 | $0 (2018) |
| Amgen Inc. | $51.28 | 1 | $0 (2024) |
| Eisai Inc. | $16.44 | 1 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.69 | 1 | $0 (2018) |
| Valeant Pharmaceuticals North America LLC | $11.50 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $80.42 | 2 | Amgen Inc. ($51.28) |
| 2023 | $977.85 | 8 | Merck Sharp & Dohme LLC ($977.85) |
| 2022 | $371,762 | 11 | Valneva Austria GmbH ($371,590) |
| 2020 | $87.00 | 1 | Eli Lilly and Company ($87.00) |
| 2019 | $3,559 | 9 | Allergan Inc. ($3,559) |
| 2018 | $110.94 | 2 | Janssen Pharmaceuticals, Inc ($95.25) |
| 2017 | $57.73 | 4 | Janssen Pharmaceuticals, Inc ($18.18) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $51.28 | General |
| Category: Cardiology | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $29.14 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/17/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $197.96 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/17/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/17/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $57.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/17/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/16/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $196.72 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/16/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $174.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/16/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $138.37 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/16/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $96.96 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/11/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $14,742.00 | Research |
| Study: AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 11/25/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $18,911.00 | Research |
| Study: AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 08/17/2022 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: VACCINE | ||||||
| 08/15/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $68,129.21 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 07/18/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $53,106.00 | Research |
| Study: AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 05/16/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $2,166.00 | Research |
| Study: AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 05/02/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $4,555.90 | Research |
| Study: AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $137.00 | Research |
| Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | ||||||
| 04/04/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $172,849.07 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 03/14/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $16,476.20 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 03/07/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $20,654.66 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $87.00 | Research |
| Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | ||||||
| 12/31/2019 | Allergan Inc. | — | — | Cash or cash equivalent | $1,859.13 | Research |
| Study: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis | ||||||
| 08/11/2019 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $370.15 | General |
| 08/11/2019 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $370.15 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $278,109 | 4 |
| AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $93,481 | 5 |
| A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis | Allergan Inc. | $1,859 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $224.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 501 | 507 | $89,224 | $27,664 |
| 2022 | 14 | 817 | 886 | $139,822 | $41,201 |
| 2021 | 11 | 567 | 578 | $104,119 | $35,718 |
| 2020 | 9 | 299 | 442 | $48,746 | $13,783 |
Total Patients
2,184
Total Services
2,413
Medicare Billing
$118,366
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 200 | 205 | $39,022 | $11,125 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 113 | $30,535 | $8,725 | 28.6% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 67 | 68 | $7,630 | $4,281 | 56.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 18 | $6,660 | $1,867 | 28.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $2,766 | $848.34 | 30.7% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 28 | 28 | $1,120 | $453.60 | 40.5% |
| 87807 | Detection test by immunoassay with direct visual observation for respiratory syncytial virus | Office | 2023 | 12 | 12 | $360.00 | $154.08 | 42.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 12 | $513.00 | $101.13 | 19.7% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2023 | 20 | 20 | $400.00 | $67.35 | 16.8% |
| 81003 | Automated urinalysis test | Office | 2023 | 19 | 19 | $218.00 | $41.80 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 155 | 158 | $42,660 | $12,755 | 29.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 193 | 202 | $38,380 | $11,817 | 30.8% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2022 | 149 | 152 | $21,280 | $4,631 | 21.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 62 | 62 | $14,260 | $4,361 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $11,900 | $3,800 | 31.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 14 | $5,180 | $1,877 | 36.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 56 | 57 | $2,850 | $944.78 | 33.2% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 20 | 21 | $840.00 | $341.02 | 40.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 26 | 27 | $810.00 | $277.47 | 34.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 14 | 14 | $420.00 | $145.20 | 34.6% |
| 81003 | Automated urinalysis test | Office | 2022 | 42 | 44 | $440.00 | $97.31 | 22.1% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2022 | 24 | 24 | $480.00 | $86.30 | 18.0% |
| 81002 | Urinalysis, manual test | Office | 2022 | 13 | 13 | $130.00 | $44.53 | 34.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 15 | 64 | $192.00 | $23.80 | 12.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 124 | 127 | $32,082 | $10,356 | 32.3% |
About Dr. Joseph Newberg, MD
Dr. Joseph Newberg, MD is a Emergency Medicine healthcare provider based in La Porte, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013133396.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Newberg, MD has received a total of $376,635 in payments from pharmaceutical and medical device companies, with $80.42 received in 2024. These payments were reported across 37 transactions from 9 companies. The most common payment nature is "" ($373,673).
As a Medicare-enrolled provider, Newberg has provided services to 2,184 Medicare beneficiaries, totaling 2,413 services with total Medicare billing of $118,366. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Other Specialties Emergency Medicine
- Location La Porte, IN
- Active Since 04/17/2007
- Last Updated 08/15/2018
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1013133396
Products in Payments
- XARELTO (Drug) $113.43
- Repatha (Biological) $51.28
- CAPVAXIVE (Biological) $35.00
- Belviq (Drug) $16.44
- Trintellix (Drug) $15.69
- LINZESS (Drug) $11.61
- XIFAXAN (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in La Porte
Dr. Michael Hawthorne, Md, MD
Emergency Medicine — Payments: $126.82
Emergency Medicine $126.82
Najeem Ojulari, Md, MD
Emergency Medicine — Payments: $126.82
Emergency Medicine $126.82
Dr. April Bisaga, D.o, D.O
Emergency Medicine — Payments: $80.23
Emergency Medicine $80.23
Regina Iwinski, M.d, M.D
Emergency Medicine — Payments: $47.42
Emergency Medicine $47.42
Natalie Painter, D.o, D.O
Emergency Medicine
Emergency Medicine
Jeffrey Anderson, M.d., Faep, M.D., FAEP
Emergency Medicine
Emergency Medicine